Readouts For TIGIT And Alzheimer’s Drugs Will Define Roche’s Year

Will Shape Growth Trajectory

 
• By Andrew McConaghie

Roche has a lot riding on it trials to extend use of Tecentriq to challenge Keytruda in frontline NSCLC – but the wait for its Alzheimer’s readout for gantenerumab will be truly nerve-wracking.

Roche_Basel
Roche has more readouts this year and than any other European major pharma company. • Source: Alamy

More from Business

More from Scrip